AGTC News and Press, Applied Genetic Technologies Corporation From 10/07/20

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus (AA...

Applied Genetic Technologies Corporation (AGTC) Q4 2020 Earnings Conference Call September 9, 2020 8:00 A.M. ET Company Participants Sue Washer - President and Chief Executive Officer Mark Shearman - Chief Scientific Officer William Sullivan - Chief Financial Office Conference...

Gainers:  Superconductor Technologies (NASDAQ: SCON ) +85% . More news on: Superconductor Technologies Inc., Intra-Cellular Therapies, Inc., Nuverra Environmental Solutions, Inc., Stocks on the move, , Read more ...

The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with their 2020 Q4 earnings Read more ...

Applied Genetic (NASDAQ: AGTC ) : FQ4 GAAP EPS of -$0.56 misses by $0.09 . More news on: Applied Genetic Technologies Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group - - Data from Group 5 supports use of higher dose level ...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced ...

Gainers:  Shiloh Industries (NASDAQ: SHLO ) +120% . More news on: Shiloh Industries, Inc., India Globalization Capital, Inc., FTS International, Inc., Stocks on the move, , Read more ...

Applied Genetic Technologies (NASDAQ: AGTC ) will provide a management update on its planned Phase 2/3 X-Linked Retinitis Pigmentosa (XLRP) clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5 on September 9, 2020. M...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...